Evidence map›Paper›PMID 40799047›Full record

ArticleNanomedicine (London, England)2025

Influenza virus-like particles presenting

Jie Mao, Hae-Ji Kang, Su-In Heo, Fu-Shi Quan

Abstract read
In one paragraph

Article in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Advances and Translational Challenges inVeterinary sciences · 2026
    Review
  2. Veterinary sciences · 2026
    Review
  3. Protection AgainstPharmaceutics · 2026
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jie MaoDepartment of Biomedical Science, Graduate School, Kyung Hee University, Seoul, Republic of Korea.
Hae-Ji KangDepartment of Microbiology, Dongguk University College of Medicine, Gyeongju, Republic of Korea.
Su-In HeoDepartment of Biomedical Science, Graduate School, Kyung Hee University, Seoul, Republic of Korea.
Fu-Shi QuanMedical Research Center for Bioreaction to Reactive Oxygen Species and Biomedical Science Institute, Core Research Institute (CRI), Kyung Hee University, Seoul, Republic of Korea.

Funding

National Research Foundation of Korea
6 · The paper itself

Abstract

aimMATERIALS &

methodsGRA7 VLPs were constructed using an influenza M1 scaffold via the baculovirus expression system. Female BALB/c mice were immunized intranasally three times and orally challenged with lethal

resultsGRA7 VLPs induced robust

conclusionGRA7 VLPs confer strong systemic and mucosal immunity and significant protection against chronic toxoplasmosis, underscoring their potential as a promising vaccine platform.

Indexed as

Antigens, ProtozoanProtozoan ProteinsProtozoan VaccinesToxoplasmaToxoplasmosisVaccines, Virus-Like ParticleAnimalsAntibodies, ProtozoanFemaleImmunoglobulin GMiceMice, Inbred BALB CAntibodies, ProtozoanAntigens, ProtozoanImmunoglobulin GProtozoan ProteinsProtozoan VaccinesVaccines, Virus-Like ParticleGRA7immune protectionToxoplasma gondiivaccinevirus-like particles

Identifiers

PMID40799047
PMCPMC12413073

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.